Gujarat Magazine

IgA Nephropathy Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences

 Breaking News
  • No posts were found

IgA Nephropathy Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences

June 05
09:46 2024
IgA Nephropathy Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, IgA Nephropathy pipeline constitutes 30+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The IgA Nephropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

IgA Nephropathy Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the IgA Nephropathy Market.

 

Some of the key takeaways from the IgA Nephropathy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel IgA Nephropathy treatment therapies with a considerable amount of success over the years. 

  • IgA Nephropathy companies working in the treatment market are Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others, are developing therapies for the IgA Nephropathy treatment 

  • Emerging IgA Nephropathy therapies in the different phases of clinical trials are- Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others are expected to have a significant impact on the IgA Nephropathy market in the coming years.   

  • In January 2024, Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company in advanced clinical development stages focusing on innovative treatments for severe immunologic conditions, has announced the appointment of two seasoned industry experts to lead its drug programs. This includes their late-stage candidate, atacicept, now in a Phase 3 clinical trial for IgA nephropathy (IgAN). Effective immediately, Robert M. Brenner, M.D., will replace Dr. Celia Lin, M.D., as Chief Medical Officer, and William D. Turner will take on the role of Chief Development Officer.

  • In November 2023, Calliditas has announced additional promising results from the Phase III NefIgArd trial, which assesses the effectiveness of Nefecon in treating primary IgA nephropathy (IgAN). This double-blind, randomized study (NCT03643965) compares Nefecon, a novel targeted-release formulation of budesonide, with a placebo, concentrating on its impact on the estimated glomerular filtration rate (eGFR) in adult patients with IgAN.

  • In June 2023, Chinook Therapeutics, Inc. has announced a merger agreement with Novartis AG, under which Novartis will acquire Chinook for $40 per share in cash, totaling $3.2 billion. This offer represents an 83% premium over Chinook’s 60-day volume-weighted average stock price and a 67% premium over its closing price on June 9, 2023. Additionally, Chinook shareholders will receive contingent value rights (CVRs), which allow for payments of up to $4 per share based on the achievement of specific regulatory milestones for Chinook’s lead product candidate, atrasentan.

 

IgA Nephropathy Overview

IgA nephropathy, also known as Berger’s disease, is a kidney disorder characterized by the buildup of immunoglobulin A (IgA) deposits in the glomeruli, which are the tiny filters in the kidneys that remove waste and excess fluids from the blood. IgA is a type of antibody that helps the immune system fight infections, but in IgA nephropathy, abnormal deposits of IgA accumulate in the kidneys, leading to inflammation and damage.

 

Get a Free Sample PDF Report to know more about IgA Nephropathy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight

 

Emerging IgA Nephropathy Drugs Under Different Phases of Clinical Development Include:

  • Sibeprenlimab: Visterra

  • Atrasentan: Chinook Therapeutics

  • LNP023: Novartis Pharmaceuticals

  • Research programme: IgA proteases Selecta Biosciences

  • AP 305: Shanghai Alebund Pharmaceuticals

  • ADR-001: Rohto Pharmaceutical

  • MY 008: Wuhan Createrna Science and Technology

  • SHR-2010: Guangdong Hengrui Pharmaceutical

  • IONIS FB: LRx Ionis Pharmaceuticals

  • HR19042: Jiangsu HengRui Medicine Co., Ltd.

  • Sparsentan: Travere Therapeutics

  • HR19042: Jiangsu HengRui Medicine Co., Ltd.

 

IgA Nephropathy Route of Administration

IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

IgA Nephropathy Molecule Type

IgA Nephropathy Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

IgA Nephropathy Pipeline Therapeutics Assessment

  • IgA Nephropathy Assessment by Product Type

  • IgA Nephropathy By Stage and Product Type

  • IgA Nephropathy Assessment by Route of Administration

  • IgA Nephropathy By Stage and Route of Administration

  • IgA Nephropathy Assessment by Molecule Type

  • IgA Nephropathy by Stage and Molecule Type

 

DelveInsight’s IgA Nephropathy Report covers around 30+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further IgA Nephropathy product details are provided in the report. Download the IgA Nephropathy pipeline report to learn more about the emerging IgA Nephropathy therapies

 

Some of the key companies in the IgA Nephropathy Therapeutics Market include:

Key companies developing therapies for IgA Nephropathy are – Arrowhead Pharmaceuticals, Takeda, Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Apellis Pharmaceuticals, Inc., and others.

 

IgA Nephropathy Pipeline Analysis:

The IgA Nephropathy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.

  • IgA Nephropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about IgA Nephropathy drugs and therapies

 

IgA Nephropathy Pipeline Market Drivers

  • Increase in prevalence of IgA Nephropathy (IgAN), increment in the number of government initiatives to spread awareness are some of the important factors that are fueling the IgA Nephropathy Market.

 

IgA Nephropathy Pipeline Market Barriers

  • However, lack of in-depth understanding of the disease pathogenesis, the unreported and undiagnosed IgA Nephropathy cases and other factors are creating obstacles in the IgA Nephropathy Market growth.

 

Scope of IgA Nephropathy Pipeline Drug Insight    

  • Coverage: Global

  • Key IgA Nephropathy Companies: Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others

  • Key IgA Nephropathy Therapies: Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others

  • IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies

  • IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers 

 

Request for Sample PDF Report for IgA Nephropathy Pipeline Assessment and clinical trials

 

Table of Contents

1. IgA Nephropathy Report Introduction

2. IgA Nephropathy Executive Summary

3. IgA Nephropathy Overview

4. IgA Nephropathy- Analytical Perspective In-depth Commercial Assessment

5. IgA Nephropathy Pipeline Therapeutics

6. IgA Nephropathy Late Stage Products (Phase II/III)

7. IgA Nephropathy Mid Stage Products (Phase II)

8. IgA Nephropathy Early Stage Products (Phase I)

9. IgA Nephropathy Preclinical Stage Products

10. IgA Nephropathy Therapeutics Assessment

11. IgA Nephropathy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. IgA Nephropathy Key Companies

14. IgA Nephropathy Key Products

15. IgA Nephropathy Unmet Needs

16 . IgA Nephropathy Market Drivers and Barriers

17. IgA Nephropathy Future Perspectives and Conclusion

18. IgA Nephropathy Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Recent Posts

Advanced Melanoma Pipeline Outlook Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

Read Full Article

Categories